World’s first vaccine for ovarian cancer could wipe out the disease
A new blood test shows promise in accurately detecting ovarian cancer at its earliest stages, potentially transforming patient care.
Developed by AOA Dx, the innovative test identifies two distinct blood markers and uses machine learning to recognise subtle patterns of lipids and proteins shed by cancer cells.
Studies demonstrated high accuracy, with the test detecting ovarian cancer across all stages with 93 per cent accuracy in Colorado samples and 92 per cent in Manchester samples.
Experts are optimistic that, pending regulatory approval, this test could be integrated into NHS services, offering a significant improvement over current diagnostic methods.
Ovarian cancer affects approximately 7,500 women in the UK annually, predominantly those over 50, and is often diagnosed too late when it is harder to treat.